{"id":"W2098276344","doi":"10.1016/s1470-2045(13)70335-8","title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":436,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research","keywords":"Medicine; Bevacizumab; Breast cancer; Internal medicine; Oncology; Anthracycline; Clinical endpoint; Taxane; Chemotherapy; Population; Triple-negative breast cancer; Ixabepilone; Cancer; Surgery; Randomized controlled trial; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018357,0.001052047,0.002166855,0.0002476422,0.0003259037,0.0009379574,0.0006860237,0.001377925,0.004912582],"category_scores_gemma":[0.002059,0.0003591551,0.001462584,0.000311488,0.0006484814,0.0007473347,0.0003879528,0.002718004,0.0008146414],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009257782,"about_ca_system_score_gemma":0.0008497613,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002086256,"about_ca_topic_score_gemma":0.00567585,"domain_scores_codex":[0.9993553,0.0003830543,0.0000206926,0.00008734304,0.00005022677,0.0001034009],"domain_scores_gemma":[0.9990808,0.000300592,0.0001848856,0.0000816347,0.00004631067,0.0003058554],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9573738,0.003150286,0.0008764521,0.0006912744,0.001771657,0.00004759689,0.00007250424,0.0005365253,0.003347571,0.0001734969,0.00235234,0.02960656],"study_design_scores_gemma":[0.9485826,0.04438702,0.00341131,0.00005847236,0.0009808559,0.00005766314,0.00002968733,0.0002907763,0.0003218164,0.0002243819,0.001638297,0.00001705519],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9794688,0.01048298,0.0006237327,0.001706781,0.0004980798,0.00140209,0.00133655,0.0001215848,0.004359328],"genre_scores_gemma":[0.9795701,0.005393429,0.001867473,0.002342637,0.0004247083,0.002084282,0.002300142,0.00004986158,0.005967357],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004912582,"threshold_uncertainty_score":0.01643425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03051684271619915,"score_gpt":0.3359500223103854,"score_spread":0.3054331795941863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}